Specialist Consultant Referral Form

Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg

I am referring my patient to you for consultation in the initiation of therapy with Nurtec® ODT (rimegepant).
The patient's insurance plan requires that a prescription for Nurtec ODT be written in consultation with or by a specialist.
Please provide the information requested below.

REFERRING PHYSICIAN		CONSULTING PHYSICIAN	
Name:		Name:	
Phone Number:	Fax Number:	Phone Number:	Fax Number:
NPI:		NPI:	

PATIENT INFORMATION

Patient Name:		Date of Birth:
Patient Address:	Patient Phone Number:	Patient Mobile Number:
Patient Insurance Plan:	Member ID:	Group Number:

PATIENT MEDICAL AND TREATMENT HISTORY ☐ ATTACHED ☐ BELOW

1. The patient is being prescribed Nurtec ODT for ☐ Acute treatment of migraine with or without aura ☐ Preventive treatment of episodic migraine

2. Patient diagnosis[1,*]:
☐ G43 Migraine
☐ G43.00 Migraine without aura, not intractable
☐ G43.01 Migraine without aura, intractable
☐ G43.10 Migraine with aura, not intractable
☐ G43.11 Migraine with aura, intractable
☐ G43.90 Migraine, unspecified, not intractable
☐ Other (specify ICD-10-CM code):

3. How many migraine/headache days does the patient experience per month?

4. Has the patient tried one or more triptans? ☐ Yes ☐ No
List the names of previous triptan therapies, including dates of use, dosage, and frequency:

5. Has the patient tried one or more prophylactic therapies? ☐ Yes ☐ No
List the names of previous prophylactic therapies, including dates of use, dosage, and frequency:

6. Did the patient discontinue triptan and/or prophylactic therapy due to therapeutic failure, contraindication, or intolerance/adverse events? ☐ Yes ☐ No
Describe the reasons for discontinuation:

7. Other pertinent medical history or drug treatment:	8. Allergies:

*This information is intended for informational purposes only and is not a comprehensive description of potential coding requirements for Nurtec ODT. Coding and coverage policies change periodically and often without warning. The healthcare provider is solely responsible for determining coverage and reimbursement parameters and accurate and appropriate coding for treatment of their patients. The information provided in this section should not be considered a guarantee of coverage or reimbursement for Nurtec ODT. The codes shown above are only general suggestions and are not intended to encourage or suggest a use of any drug that is inconsistent with FDA-approved use.

See next page for additional fields to complete.

INDICATIONS

Nurtec ODT is indicated in adults for the:

- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Please see next page for additional Important Safety Information and click here for full Prescribing Information.

Nurtec® ODT (rimegepant)
orally disintegrating tablets 75 mg

Patient Name: _____ Date of Birth: _____

PAYER REQUIREMENT (CHOOSE ONE):

☐ **Payer requires that prescription be written by a specialist (appointment requested)**
My patient's insurance requires that their prescription for initiation with Nurtec ODT be written by a specialist. Documentation of patient's medical history is attached.

☐ **Payer requires prescription be written in consultation with a specialist (please complete section below)**

TO BE COMPLETED BY THE CONSULTING PHYSICIAN:

The patient's payer requires a consultation with a specialist in order to authorize coverage for Nurtec ODT. Please complete the following section and fax or email the entire form back to the referring physician.

Consulting Physician Notes:

Consulting Physician Name:	**Consulting Physician Specialty:**

☐ **Additional follow-up by consulting physician required:**

☐ **Contact office to schedule a phone consultation**

☐ **Schedule patient appointment for in-office evaluation**

☐ **Provide additional supporting information:**

Consulting Physician Signature:	**Date:**

IMPORTANT SAFETY INFORMATION (cont.)

Warnings and Precautions

Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including Nurtec ODT, in the postmarketing setting.

Monitor patients for new-onset hypertension or worsening of pre-existing hypertension and consider whether discontinuation is warranted.

Raynaud's Phenomenon: Development of Raynaud's phenomenon and recurrence or worsening of pre-existing Raynaud's phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including Nurtec ODT.

If signs or symptoms of Raynaud's phenomenon develop, discontinue Nurtec ODT. Patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud's phenomenon should be monitored for and informed about the possibility of worsening or recurrence of signs and symptoms.

Adverse Reactions: The most common adverse reactions for Nurtec ODT vs placebo were nausea (2.7% vs 0.8%) and abdominal pain/dyspepsia (2.4% vs 0.8%).

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4 or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp.

Use in Specific Populations: *Pregnancy:* It is not known if Nurtec ODT can harm an unborn baby. *Lactation:* The transfer of rimegepant into breast milk is low (<1%). *Hepatic impairment:* Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment:* Avoid use in patients with end-stage renal disease.

Please click here for full Prescribing Information.

Reference: 1. Centers for Medicare & Medicaid Services. ICD-10-CM index to diseases and injuries. https://www.cms.gov/files/zip/2025-code-tables-tabular-and-index-april.zip. Updated January 15, 2025. Accessed April 21, 2025.

April 2025 PP-NNT-USA-4317

Pfizer